NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
GlaxoSmithKline
GlaxoSmithKline
EMD Serono
National Institutes of Health Clinical Center (CC)